The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2.
Biochem Biophys Res Commun
; 538: 63-71, 2021 01 29.
Article
em En
| MEDLINE
| ID: mdl-33288200
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an unprecedented global health crisis. It is particularly urgent to develop clinically effective therapies to contain the pandemic. The main protease (Mpro) and the RNA-dependent RNA polymerase (RdRP), which are responsible for the viral polyprotein proteolytic process and viral genome replication and transcription, respectively, are two attractive drug targets for SARS-CoV-2. This review summarizes up-to-date progress in the structural and pharmacological aspects of those two key targets above. Different classes of inhibitors individually targeting Mpro and RdRP are discussed, which could promote drug development to treat SARS-CoV-2 infection.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Inibidores Enzimáticos
/
Inibidores de Protease de Coronavírus
/
RNA-Polimerase RNA-Dependente de Coronavírus
/
Proteases 3C de Coronavírus
/
SARS-CoV-2
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article